齐拉西酮作为氯氮平治疗重度双相情感障碍患者的辅助疗法。
Ziprasidone as adjunctive therapy in severe bipolar patients treated with clozapine.
作者信息
Bartolommei Natalia, Casamassima Francesco, Pensabene Laura, Luchini Federica, Benvenuti Antonella, Di Paolo Antonello, Cosentino Luca, Mauri Mauro, Lattanzi Lorenzo
机构信息
Dipartimento di Medicina Clinica e Sperimentale, Sezione di Psichiatria, Università di Pisa, Azienda Ospedaliero-Universitaria Pisana, Via Roma, No. 67, 56126 Pisa, Italy.
出版信息
ISRN Psychiatry. 2014 Apr 7;2014:904829. doi: 10.1155/2014/904829. eCollection 2014.
Aim. To confirm the efficacy and tolerability of ziprasidone as adjunctive therapy in bipolar patients partially responding to clozapine or with persisting negative symptoms, overweight, or with metabolic syndrome. Methods. Eight patients with psychotic bipolar disorder were tested with the BPRS, the HAM-D, and the CGI at T0 and retested after 2 weeks (T1). Plasma clozapine and norclozapine levels and BMI were tested at T0 and T1. Results. Ziprasidone was well tolerated by all the patients. BPRS and HAM-D scores were reduced in all patients. BMI was reduced in patients with a BMI at T0 higher than 25. Plasma levels of clozapine and norclozapine showed an irregular course.
目的。确认齐拉西酮作为辅助治疗药物，对于部分响应氯氮平治疗或存在持续阴性症状、超重或患有代谢综合征的双相情感障碍患者的疗效和耐受性。方法。8例患有精神病性双相情感障碍的患者在T0期接受简明精神病评定量表（BPRS）、汉密尔顿抑郁量表（HAM-D）和临床总体印象量表（CGI）测试，并在2周后（T1）重新测试。在T0期和T1期测试血浆氯氮平和去甲氯氮平水平以及体重指数（BMI）。结果。所有患者对齐拉西酮耐受性良好。所有患者的BPRS和HAM-D评分均降低。T0期BMI高于25的患者BMI降低。氯氮平和去甲氯氮平的血浆水平呈不规则变化。
Zotero 插件